Rigel Pharmaceuticals (RIGL) Finished Goods (2018 - 2026)

Rigel Pharmaceuticals' Finished Goods history runs 9 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Finished Goods rose 9.05% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $4.1 million (up 9.05% YoY), while the FY2025 annual figure was $4.7 million, down 6.02% from the prior year.
• Finished Goods for Q1 2026 stood at $4.1 million, down from $4.7 million in the prior quarter.
• The five-year high for Finished Goods was $5.8 million in Q3 2024, with the low at $1.1 million in Q2 2022.
• The 5-year median for Finished Goods is $2.0 million (2022), against an average of $2.8 million.
• The sharpest annual moves came in 2024 and 2025: Finished Goods soared 232.49% in 2024, then sank 69.37% in 2025.
• Rigel Pharmaceuticals' Finished Goods stood at $1.9 million in 2022, then slipped by 20.8% to $1.5 million in 2023, then jumped by 232.49% to $5.0 million in 2024, then decreased by 6.02% to $4.7 million in 2025, then slipped by 13.05% to $4.1 million in 2026.
• Business Quant data shows RIGL's Finished Goods at $4.1 million in Q1 2026, $4.7 million in Q4 2025, and $1.8 million in Q3 2025.